GlassScriptPhysician profile
Toni D Microulis
NPI 1679658777
$5,061.34
in general payments reported to CMS, 2019-2025
15 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $2,071 · 2023: $1,018 · 2024: $448 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $1,529.53 | 2022 | |
| Alkermes, INC. | $567.08 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $519.09 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $513.64 | 2021-2025 | |
| Axsome Therapeutics, INC. | $511.22 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $416.26 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $273.75 | 2021-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $175.17 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $151.33 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $99.17 | 2023 | Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $82.36 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $77.06 | 2021 | |
| Lundbeck LLC | $64.40 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $59.40 | 2021 | |
| Vanda Pharmaceuticals INC. | $21.88 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Microulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.